Risk of adverse events with concomitant use of Atorvastatin or Simvastatin and glucose-lowering drugs (Thiazolidinediones, Metformin, Sulfonylurea, Insulin, and Acarbose)

American Journal of Cardiology

Volumn 89, Issue 11, 2002, Pages 1308-1310

  Alsheikh Ali, Alawi A ^a   Abourjaily, Heather M ^b   Karas, Richard H ^a,c  

^a Preventive Cardiology Center   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; ATORVASTATIN; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ADULT; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; DATA BASE; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; PANCREAS DISEASE; PRIORITY JOURNAL;

ACARBOSE; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTICHOLESTEREMIC AGENTS; CHROMANS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PYRROLES; SIMVASTATIN; SULFONYLUREA COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0036606906     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02334-2     Document Type: Article

References (4)

1. Recent developments and emerging therapies for type 2 diabetes mellitus
2. Thiazolidinediones and liver toxicity
3. Hepatocellular injury in a patient recieving rosiglitazone
4. Hepatic failure in a patient taking rosiglitazone